L.A. van Herwerden

Are you L.A. van Herwerden?

Claim your profile

Publications (4)2.88 Total impact

  • Article: Systemic embolisation as presentation and recurrence of cardiac myxoma two years after surgery
    C. Liesting, F. Z. Ramjankhan, L. A. van Herwerden, M. J. M. Kofflard
    [show abstract] [hide abstract]
    ABSTRACT: Primary cardiac tumours are rare when compared with metastatic involvement. The majority of primary cardiac tumours are benign and in adults the majority of these masses are myxomas. The treatment is surgical removal because of the risk of embolisation and/or cardiovascular complications. We describe a female presenting with systemic embolisation and recurrence of cardiac myxoma after surgery. Recurrence of myxoma is rare after surgery in case of solitary tumours but more frequent in patients with familial myxomas in association with the Carney complex. Genetic analysis revealed a mutation in the PRKAR1A gene that has never been described before. (Neth Heart J 2010;18:499-502.) Myxoma-Recurrence-Embolism-Interleukin-Carney Complex
    Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 04/2012; 18(10):499-502. · 1.44 Impact Factor
  • Article: Systemic embolisation as presentation and recurrence of cardiac myxoma two years after surgery.
    C Liesting, F Z Ramjankhan, L A van Herwerden, M J M Kofflard
    [show abstract] [hide abstract]
    ABSTRACT: Primary cardiac tumours are rare when compared with metastatic involvement. The majority of primary cardiac tumours are benign and in adults the majority of these masses are myxomas. The treatment is surgical removal because of the risk of embolisation and/or cardiovascular complications. We describe a female presenting with systemic embolisation and recurrence of cardiac myxoma after surgery. Recurrence of myxoma is rare after surgery in case of solitary tumours but more frequent in patients with familial myxomas in association with the Carney complex. Genetic analysis revealed a mutation in the PRKAR1A gene that has never been described before. (Neth Heart J 2010;18:499502.).
    Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 10/2010; 18(10):499-502. · 1.44 Impact Factor
  • Article: Systemic embolisation as presentation and recurrence of cardiac myxoma two years after surgery.
    C Liesting, F.Z. Ramjankhan, L.A. van Herwerden, MJ Kofflard
  • Source
    Article: A patient with four artificial heart valves after ergotamine therapy
    M. Bijl, T.W. Galema, L.A. van Herwerden, M J M Kofflard, P.N.W.M. Breuls, R.B.A. van de Brink
    [show abstract] [hide abstract]
    ABSTRACT: A 67-year-old female was evaluated in the out-patient clinic because of shortness of breath on exertion and regular spells of fever. She had been taking ergotamine tartrate to treat migraine for more than 30 years. The patient had undergone aortic-valve replacement for aortic insufficiency three years before. On echocardiographic evaluation, severe retraction and insufficiency of the remaining native heart valves was demonstrated. Endocarditis and carcinoid syndrome were excluded. The mitral, tricuspid and pulmonary valves were all replaced by a mechanical valvular prosthesis. Pathological-anatomical evaluation of the three replaced valves and the aortic valve replaced three years earlier disclosed identical findings, compatible with long-term ergotamine use. Nine months after surgery, a sick sinus syndrome developed necessitating implantation of a DDDR pacemaker with a right atrial and a coronary sinus lead. Functional class according to the New York Heart Association improved from class III to I. After stopping the ergotamine, the fever disappeared. However, the migraine spells reoccurred which are now being treated with paracetamol.
Browse more researchers